JCEM:胸椎骨折在COVID-19患者中常见且可预测疾病预后

2020-10-22 MedSci原创 MedSci原创

VFs可能整合了COVID-19患者的心肺风险,是一种有用且易于测量脆弱性和不良预后的临床指标。研究人员建议应对所有接受胸部X线检查的可疑COVID-19患者进行胸椎形态学评估。

COVID-19已成为全球最受关注的医学问题。尽管有几项研究调查了COVID-19患者的临床特征,但尚未有研究报道椎骨骨折(VFs)患病率的数据。VF可能会影响心肺功能和疾病结局,近日,内分泌和代谢性疾病领域权威杂志Journal of Clinical Endocrinology & Metabolism上发表了一篇研究文章,该研究旨在评估VF的患病率和对COVID-19患者临床结局的影响。

这是一项在意大利三级医疗医院进行的回顾性队列研究,研究人员纳入了到急诊科就诊且接受侧位胸部X光检查的COVID-19患者。研究人员通过胸部X射线对椎体形状进行半定量评估来检测有无VF。

该研究共纳入了114例患者,其中41例(36%)检测出存在胸VF。VF患者年龄较大,并且更容易受到高血压和冠状动脉疾病的影响(分别为p<0.001,p=0.007,p=0.034)。

VFs组有36例(88%)患者入院,而无VFs组有54例(74%)患者入院(p=0.08)。与没有VF的患者相比,有VF的患者更需要无创机械通气(p=0.02)。VFs组的死亡率为22%,无VFs组的死亡率为10%(p=0.07)。特别是重度VF患者的死亡率高于中度和轻度VF患者(p=0.04)。

由此可见,VFs可能整合了COVID-19患者的心肺风险,是一种有用且易于测量脆弱性和不良预后的临床指标。研究人员建议应对所有接受胸部X线检查的可疑COVID-19患者进行胸椎形态学评估。

原始出处:

Luigi di Filippo,et al.Radiological Thoracic Vertebral Fractures are highly prevalent in COVID-19 and predict disease outcomes.JCEM.2020.https://doi.org/10.1210/clinem/dgaa738

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2063373, encodeId=481820633e341, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Aug 25 03:51:21 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777991, encodeId=fcd91e7799173, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Tue Nov 10 11:51:21 CST 2020, time=2020-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739329, encodeId=53991e393291d, content=<a href='/topic/show?id=908be07412a' target=_blank style='color:#2F92EE;'>#疾病预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70741, encryptionId=908be07412a, topicName=疾病预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b25634523578, createdName=ms2694732865965676, createdTime=Fri Aug 06 05:51:21 CST 2021, time=2021-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297486, encodeId=3c12129e486a9, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Sat Oct 24 05:51:21 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489989, encodeId=0d8e14899895e, content=<a href='/topic/show?id=2d258411ea9' target=_blank style='color:#2F92EE;'>#胸椎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84117, encryptionId=2d258411ea9, topicName=胸椎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d688662973, createdName=yyj065, createdTime=Sat Oct 24 05:51:21 CST 2020, time=2020-10-24, status=1, ipAttribution=)]
    2021-08-25 achengzhao
  2. [GetPortalCommentsPageByObjectIdResponse(id=2063373, encodeId=481820633e341, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Aug 25 03:51:21 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777991, encodeId=fcd91e7799173, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Tue Nov 10 11:51:21 CST 2020, time=2020-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739329, encodeId=53991e393291d, content=<a href='/topic/show?id=908be07412a' target=_blank style='color:#2F92EE;'>#疾病预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70741, encryptionId=908be07412a, topicName=疾病预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b25634523578, createdName=ms2694732865965676, createdTime=Fri Aug 06 05:51:21 CST 2021, time=2021-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297486, encodeId=3c12129e486a9, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Sat Oct 24 05:51:21 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489989, encodeId=0d8e14899895e, content=<a href='/topic/show?id=2d258411ea9' target=_blank style='color:#2F92EE;'>#胸椎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84117, encryptionId=2d258411ea9, topicName=胸椎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d688662973, createdName=yyj065, createdTime=Sat Oct 24 05:51:21 CST 2020, time=2020-10-24, status=1, ipAttribution=)]
    2020-11-10 smallant2015
  3. [GetPortalCommentsPageByObjectIdResponse(id=2063373, encodeId=481820633e341, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Aug 25 03:51:21 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777991, encodeId=fcd91e7799173, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Tue Nov 10 11:51:21 CST 2020, time=2020-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739329, encodeId=53991e393291d, content=<a href='/topic/show?id=908be07412a' target=_blank style='color:#2F92EE;'>#疾病预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70741, encryptionId=908be07412a, topicName=疾病预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b25634523578, createdName=ms2694732865965676, createdTime=Fri Aug 06 05:51:21 CST 2021, time=2021-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297486, encodeId=3c12129e486a9, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Sat Oct 24 05:51:21 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489989, encodeId=0d8e14899895e, content=<a href='/topic/show?id=2d258411ea9' target=_blank style='color:#2F92EE;'>#胸椎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84117, encryptionId=2d258411ea9, topicName=胸椎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d688662973, createdName=yyj065, createdTime=Sat Oct 24 05:51:21 CST 2020, time=2020-10-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2063373, encodeId=481820633e341, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Aug 25 03:51:21 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777991, encodeId=fcd91e7799173, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Tue Nov 10 11:51:21 CST 2020, time=2020-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739329, encodeId=53991e393291d, content=<a href='/topic/show?id=908be07412a' target=_blank style='color:#2F92EE;'>#疾病预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70741, encryptionId=908be07412a, topicName=疾病预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b25634523578, createdName=ms2694732865965676, createdTime=Fri Aug 06 05:51:21 CST 2021, time=2021-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297486, encodeId=3c12129e486a9, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Sat Oct 24 05:51:21 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489989, encodeId=0d8e14899895e, content=<a href='/topic/show?id=2d258411ea9' target=_blank style='color:#2F92EE;'>#胸椎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84117, encryptionId=2d258411ea9, topicName=胸椎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d688662973, createdName=yyj065, createdTime=Sat Oct 24 05:51:21 CST 2020, time=2020-10-24, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2063373, encodeId=481820633e341, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Wed Aug 25 03:51:21 CST 2021, time=2021-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1777991, encodeId=fcd91e7799173, content=<a href='/topic/show?id=eb9610265ed' target=_blank style='color:#2F92EE;'>#JCEM#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10265, encryptionId=eb9610265ed, topicName=JCEM)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2a4439169927, createdName=smallant2015, createdTime=Tue Nov 10 11:51:21 CST 2020, time=2020-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739329, encodeId=53991e393291d, content=<a href='/topic/show?id=908be07412a' target=_blank style='color:#2F92EE;'>#疾病预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70741, encryptionId=908be07412a, topicName=疾病预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b25634523578, createdName=ms2694732865965676, createdTime=Fri Aug 06 05:51:21 CST 2021, time=2021-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297486, encodeId=3c12129e486a9, content=<a href='/topic/show?id=c0385134ab' target=_blank style='color:#2F92EE;'>#COVID-19患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5134, encryptionId=c0385134ab, topicName=COVID-19患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6976269, createdName=zhangph, createdTime=Sat Oct 24 05:51:21 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489989, encodeId=0d8e14899895e, content=<a href='/topic/show?id=2d258411ea9' target=_blank style='color:#2F92EE;'>#胸椎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=84117, encryptionId=2d258411ea9, topicName=胸椎)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d688662973, createdName=yyj065, createdTime=Sat Oct 24 05:51:21 CST 2020, time=2020-10-24, status=1, ipAttribution=)]
    2020-10-24 yyj065

相关资讯

Leukemia:DNMT3A突变的转录水平并不能预测急性髓系白血病患者的结局

达到完全缓解是患者治愈或长期生存的不可或缺的先决条件。形态学上的完全缓解,即骨髓原始细胞<5%,对临床医生来说仍是有效的评估诱导治疗效果的必需信息。

Leukemia:科学家发现PTEN突变类型与T-ALL疾病预后相关

PTEN缺失对疾病预后的影响也与其基因突变的类型有关,而这也提示在临床治疗中对异常类型的细节分析更有利于对疾病危险分级。